It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
As COVID-19 continues to spread rapidly worldwide and variants continue to emerge, the development and deployment of safe and effective vaccines are urgently needed. Here, we developed an mRNA vaccine based on the trimeric receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein fused to ferritin-formed nanoparticles (TF-RBD). Compared to the trimeric form of the RBD mRNA vaccine (T-RBD), TF-RBD delivered intramuscularly elicited robust and durable humoral immunity as well as a Th1-biased cellular response. After further challenge with live SARS-CoV-2, immunization with a two-shot low-dose regimen of TF-RBD provided adequate protection in hACE2-transduced mice. In addition, the mRNA template of TF-RBD was easily and quickly engineered into a variant vaccine to address SARS-CoV-2 mutations. The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants. This mRNA vaccine based on the encoded self-assembled nanoparticle-based trimer RBD provides a reference for the design of mRNA vaccines targeting SARS-CoV-2.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442); Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738); Guangxi University, State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources & Laboratory of Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Nanning, China (GRID:grid.256609.e) (ISNI:0000 0001 2254 5798)
2 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
3 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442); Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738)
4 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442)
5 Guangxi University, State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources & Laboratory of Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Nanning, China (GRID:grid.256609.e) (ISNI:0000 0001 2254 5798)
6 Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738); Tsinghua University, Tsinghua-Peking Center for Life Sciences, School of Medicine, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
7 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442); Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738); Guangxi University, State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources & Laboratory of Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Nanning, China (GRID:grid.256609.e) (ISNI:0000 0001 2254 5798); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Institute of Microbiology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China (GRID:grid.458488.d) (ISNI:0000 0004 0627 1442)